A patient who underwent kidney transplantation is being educated about the types of transplant rejection. Which statement about hyperacute rejection is true?

Choice A rationale This statement is incorrect because hyperacute rejection occurs almost immediately, usually within minutes to hours after the graft is vascularized. It does not take several days to develop; that timeframe is more characteristic of acute rejection, which typically occurs within the first few weeks or months. Hyperacute rejection is a rapid and violent immune response that happens while the patient is still in the operating room or very shortly after the surgical procedure is completed. Choice B rationale This statement is false because hyperacute rejection is generally irreversible. Once the process begins, the damage to the transplanted organ is so severe and rapid that increasing immunosuppressive medications like corticosteroids or monoclonal antibodies will not save the graft. The only effective treatment for hyperacute rejection is the immediate surgical removal of the transplanted organ to prevent a systemic inflammatory response and further complications for the recipient, who must then return to dialysis. Choice C rationale This is the correct statement. Hyperacute rejection is caused by pre-existing recipient antibodies that react against the donor's antigens, specifically the ABO blood group or human leukocyte antigens. This binding triggers the complement system and a massive inflammatory cascade. This leads to widespread endothelial damage, platelet aggregation, and capillary thrombosis within the new organ. The resulting ischemia and necrosis cause the organ to turn blue or mottled almost immediately after blood flow is restored. Choice D rationale This statement is inaccurate because the symptoms of hyperacute rejection are immediate rather than occurring within two weeks. While fever and pain at the transplant site can occur, they happen immediately. The two-week timeframe is much more common for acute rejection, which is mediated by T-cells rather than pre-existing antibodies. Hyperacute rejection is now rare due to improved cross-matching techniques that identify these pre-formed antibodies before the transplant surgery is ever performed.